Nuo Therapeutics, Inc. (AURX) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts AURX Hot Sheet
Join SI Premium – FREE
Nuo Therapeutics, Inc. (OTC: AURX) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.02 million.
For earnings history and earnings-related data on Nuo Therapeutics, Inc. (AURX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Core Natural Resources (CNR) to Neutral
- Mercury Systems (MRCY) Misses Q4 EPS by 2c
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
